![]() VIARTIS
|
||||||||||||
PARKINSON'S DISEASE NEWS |
||||||||||||
|
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].
16th July 2016 - News release ONGENTYS - NEW COMT INHIBITOR FOR PARKINSON'S DISEASE
The European Commission has approved Ongentys (opicapone) for use alongside preparations of L-dopa and dopa decarboxylase inhibitors (such as Sinemet and Madopar) in people with Parkinson's Disease who have end-of-dose motor fluctuations, and who cannot be stabilised on those combinations. Opicapone is a new COMT inhibitor. COMT inhibitors aim to maintain dopamine levels for longer.
The most common adverse effects are disorders of the nervous system (brain and spinal cord). Among these, dyskinesia may affect around 2 in 10 people. For more information go to the Ongentys page at the : European Medicines Agency Ongentys For more news go to Parkinson's Disease News
|
|
||||||||||
![]() |
||||||||||||
�2006-2016 Viartis | ||||||||||||
2016-07-15 19:49:42 | ||||||||||||
[email protected] |